Compare Enveric Biosciences Inc (ENVB) vs General Mills, Inc. (GIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs General Mills, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while General Mills, Inc. trades at $37.94 (market cap $19.89B). The key difference: General Mills, Inc. is far larger — about 3208.1× Enveric Biosciences Inc's market cap, and General Mills, Inc. pays a 6.55% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | GIS | |
|---|---|---|
Market Cap | $6.20M | $19.89B |
Sector | Health | Consumer Staples |
52-Week High | $17.40 | $51.11 |
52-Week Low | $1.27 | $32.17 |
Enterprise Value | $1.30M | $33.37B |
Dividend Yield | — | 6.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
General Mills (GIS) trades at $36.89, up 2.27% today, with a bullish technical signal from moving averages. The stock shows mixed fundamentals with declining revenue ($19.49B in 2025) and negative net income margin (-0.48%), though it beat Q2 2026 EPS estimates. Valuation appears attractive with P/E of 9.23 and P/S of 1.08. Recent news highlights cost-saving initiatives and new product launches, while analyst consensus remains cautious with 61% hold ratings.
Outlook: GIS faces headwinds from soft consumer demand and margin pressure, but its cost-saving strategy and dividend yield offer some stability. Risks include competitive threats and high debt levels. The stock presents a value opportunity for income-focused investors if management can execute its turnaround plan effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
